1
|
Marjańska M, Weigand SD, Preboske G, Wengenack TM, Chamberlain R, Curran GL, Poduslo JF, Garwood M, Kobayashi D, Lin JC, Jack CR. Treatment effects in a transgenic mouse model of Alzheimer's disease: a magnetic resonance spectroscopy study after passive immunization. Neuroscience 2013; 259:94-100. [PMID: 24316473 DOI: 10.1016/j.neuroscience.2013.11.052] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Revised: 11/08/2013] [Accepted: 11/25/2013] [Indexed: 12/14/2022]
Abstract
Despite the enormous public health impact of Alzheimer's disease (AD), no disease-modifying treatment has yet been proven to be efficacious in humans. A rate-limiting step in the discovery of potential therapies for humans is the absence of efficient non-invasive methods of evaluating drugs in animal models of disease. Magnetic resonance spectroscopy (MRS) provides a non-invasive way to evaluate the animals at baseline, at the end of treatment, and serially to better understand treatment effects. In this study, MRS was assessed as potential outcome measure for detecting disease modification in a transgenic mouse model of AD. Passive immunization with two different antibodies, which have been previously shown to reduce plaque accumulation in transgenic AD mice, was used as intervention. Treatment effects were detected by MRS, and the most striking finding was attenuation of myo-inositol (mIns) increases in APP-PS1 mice with both treatments. Additionally, a dose-dependent effect was observed with one of the treatments for mIns. MRS appears to be a valid in vivo measure of anti-Aβ therapeutic efficacy in pre-clinical studies. Because it is noninvasive, and can detect treatment effects, use of MRS-based endpoints could substantially accelerate drug discovery.
Collapse
Affiliation(s)
- M Marjańska
- Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN 55455, USA.
| | - S D Weigand
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55902, USA
| | - G Preboske
- Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55902, USA
| | - T M Wengenack
- Departments of Neurology, Neuroscience, and Biochemistry/Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55902, USA
| | - R Chamberlain
- Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN 55455, USA
| | - G L Curran
- Departments of Neurology, Neuroscience, and Biochemistry/Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55902, USA
| | - J F Poduslo
- Departments of Neurology, Neuroscience, and Biochemistry/Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55902, USA
| | - M Garwood
- Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN 55455, USA
| | - D Kobayashi
- Rinat, Pfizer Inc., South San Francisco, CA 94080, USA
| | - J C Lin
- Rinat, Pfizer Inc., South San Francisco, CA 94080, USA
| | - C R Jack
- Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN 55902, USA
| |
Collapse
|